Natus Medical Inc. (BABY) Updates Q4 Earnings Guidance
Natus Medical Inc. (NASDAQ:BABY) updated its fourth quarter earnings guidance on Wednesday. The company provided EPS guidance of $0.52-0.55 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.48. The company issued revenue guidance of $107-109 million, compared to the consensus revenue estimate of $104.62 million.
A number of brokerages have recently issued reports on BABY. Raymond James Financial Inc. raised shares of Natus Medical from a market perform rating to an outperform rating and set a $46.00 target price on the stock in a report on Tuesday, September 13th. Zacks Investment Research cut shares of Natus Medical from a buy rating to a hold rating in a report on Wednesday, September 28th. Finally, Benchmark Co. assumed coverage on shares of Natus Medical in a report on Tuesday, October 4th. They issued a buy rating and a $55.00 price target on the stock.
Natus Medical Inc. (NASDAQ:BABY) opened at 39.70 on Wednesday. The firm has a market cap of $1.29 billion, a price-to-earnings ratio of 34.22 and a beta of 0.78. The firm’s 50 day moving average is $41.06 and its 200-day moving average is $37.00. Natus Medical Inc. has a 12 month low of $29.54 and a 12 month high of $51.05.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings data on Wednesday, October 19th. The company reported $0.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.05. The firm earned $90.90 million during the quarter, compared to analysts’ expectations of $89.94 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The business’s revenue was down 3.9% on a year-over-year basis. During the same period last year, the company earned $0.39 earnings per share. On average, equities analysts forecast that Natus Medical Inc. will post $1.55 EPS for the current year.
In other Natus Medical news, insider James B. Hawkins acquired 10,000 shares of Natus Medical stock in a transaction dated Wednesday, September 28th. The stock was purchased at an average cost of $38.48 per share, for a total transaction of $384,800.00. Following the completion of the acquisition, the insider now directly owns 459,725 shares of the company’s stock, valued at $17,690,218. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.80% of the company’s stock.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Motley Fool Wealth Management LLC boosted its position in Natus Medical by 5.6% in the second quarter. Motley Fool Wealth Management LLC now owns 78,466 shares of the company’s stock valued at $2,966,000 after buying an additional 4,176 shares during the period. Riverhead Capital Management LLC boosted its position in Natus Medical by 1,663.0% in the second quarter. Riverhead Capital Management LLC now owns 119,460 shares of the company’s stock valued at $4,020,000 after buying an additional 112,684 shares during the period. Thrivent Financial for Lutherans boosted its position in Natus Medical by 4.7% in the second quarter. Thrivent Financial for Lutherans now owns 16,100 shares of the company’s stock valued at $609,000 after buying an additional 730 shares during the period. Rhumbline Advisers boosted its position in Natus Medical by 2.9% in the second quarter. Rhumbline Advisers now owns 44,282 shares of the company’s stock valued at $1,674,000 after buying an additional 1,242 shares during the period. Finally, Raymond James & Associates boosted its position in Natus Medical by 2.5% in the second quarter. Raymond James & Associates now owns 14,900 shares of the company’s stock valued at $563,000 after buying an additional 367 shares during the period. Institutional investors and hedge funds own 88.00% of the company’s stock.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.